Cargando…
Preliminary evidence on the safety profile of BNT162b2 (Comirnaty): new insights from data analysis in EudraVigilance and adverse reaction reports from an Italian health facility
The first vaccine against SARS-CoV-2 made available in Italy has been BNT162b2, the two-dose mRNA-based vaccine developed by Pfizer-BioNTech. The ASST Fatebenefratelli-Sacco hospital is located in one of the areas most affected by the pandemic, and to date over 2000 healthcare professionals have bee...
Autores principales: | Gringeri, Michele, Mosini, Giulia, Battini, Vera, Cammarata, Gianluca, Guarnieri, Greta, Carnovale, Carla, Clementi, Emilio, Radice, Sonia |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8171003/ https://www.ncbi.nlm.nih.gov/pubmed/34043934 http://dx.doi.org/10.1080/21645515.2021.1917236 |
Ejemplares similares
-
We Really Need Clear Guidelines and Recommendations for Safer and Proper Use of Aripiprazole and Risperidone in a Pediatric Population: Real-World Analysis of EudraVigilance Database
por: Rafaniello, Concetta, et al.
Publicado: (2020) -
Medication Errors: A Characterisation of Spontaneously Reported Cases in EudraVigilance
por: Newbould, Victoria, et al.
Publicado: (2017) -
Comparative Safety Profiles of Oncology Biosimilars vs. Originators in Europe: An Analysis of the EudraVigilance Database
por: Nikitina, Victoria, et al.
Publicado: (2023) -
Correction to: Medication Errors: A Characterisation of Spontaneously Reported Cases in EudraVigilance
por: Newbould, Victoria, et al.
Publicado: (2017) -
An algorithm to detect unexpected increases in frequency of reports of adverse events in EudraVigilance
por: Pinheiro, Luis C., et al.
Publicado: (2017)